MediWound

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MediWound reports $5M revenue, advances trials and manufacturing capacity

MediWound's Q1 2024 performance reflects solid revenue from NexoBrid, progress on manufacturing, and strategic advancements in clinical trials and FDA interactions.
While facing challenges in profitability and operational expenses, the company's strengths in innovation, market acceptance, and growth opportunities position it for future success.
With a focus on operational excellence and expansion plans, MediWound remains well-positioned to capitalize on market opportunities and drive sustainable growth.

MediWound reports revenue growth but faces profit challenges in Q2 2024

MediWound's Q2 2024 performance showed revenue growth but faced challenges with decreased gross profit and increased losses. Despite liquidity concerns, the company is capitalizing on opportunities in NexoBrid and EscharEx developments. Analyst interest in capacity expansion and trial funding indicates market potential.

MediWound reports Q3 revenue, faces revenue challenges, eyes growth opportunities

MediWound's financial performance in Q3 2024 showed revenue and profit figures.
Strengths include regulatory approvals, facility expansion, and significant investments.
Challenges lie in revenue projections, capacity constraints, and financial losses.
Opportunities exist in upcoming studies, events, and funding for product development.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in March. Details for each is a follows:

MediWound to Present at Upcoming Investor Conferences in March

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline

Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care

MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in February. Details for each is as follows:

MediWound to Present at Upcoming Investor Conferences in February

The Biomedical Advanced Research and Development Authority (BARDA) will provide supplemental funding of $9 million to MediWound Ltd  MDWD to Support NexoBrid application resubmission and the expanded access treatment protocol. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission

YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has expanded its awarded contract with MediWound by providing supplemental funding of $9 million to support the NexoBrid® BLA resubmission with the U.S. Food and Drug Administration (FDA) and the ongoing expanded access treatment protocol (NEXT).

MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol

MediWound Ltd (NASDAQ: MDWD) has posted topline results from its U.S. Phase 2 study of EscharEx for the debridement (removal of dead or infected skin tissue for wound healing) of venous leg ulcers (VLUs).  The study randomized 120 patients, of which 119 patients were treated by either EscharEx (n=46), a gel vehicle (n=43), or a non-surgical standard-of-care consisting of either enzymatic or autolytic debridement (n=30).

MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers

Primary Endpoint Met with Highly Statistically Significant Results No Observed Safety Issues Final Data R eadout Expected in Second Quarter of 2022

MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

Topline Data Expected in the First Quarter of 2022 Topline Data Expected in the First Quarter of 2022

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

Anticipate Submission for Label Extension in First Half 2022 Anticipate Submission for Label Extension in First Half 2022

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

MediWound Ltd. (MDWD) CEO Sharon Malka on Q3 2021 Results - Earnings Call Transcript

Third Quarter Revenues of $6.4 Million ; Year-to-Date 2021 Revenues Increased 21%

MediWound Reports Third Quarter 2021 Financial Results

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2021-11-16. Here's what investors need to know before the announcement.

Earnings Preview For MediWound

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 at 7:00 am Eastern Time on Tuesday, November 16, 2021.

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

Analysts Estimate MediWound (MDWD) to Report a Decline in Earnings: What to Look Out for

EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar EscharEx Treatment Demonstrated Superior Efficacy in Debridement of Eschar

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care

YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during the month of September 2021.

MediWound to Present at Upcoming Investor Conferences

Mediwound Ltd (MDWD) CEO Sharon Malka on Q2 2021 Results - Earnings Call Transcript

MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 6.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) Reports Q2 Loss, Tops Revenue Estimates

Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year

MediWound Reports Second Quarter Financial Results

YAVNE, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 at 7:00 am Eastern Time on Tuesday, August 10, 2021.

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

MediWound is developing treatment alternatives in the skin and burn products, which are set to save patients both pain and money.

MediWound: Disappointing Thus Far But Still A Strong Buy

Will MediWound (MDWD) Report Negative Q2 Earnings? What You Should Know

The FDA sent MediWound a Complete Response Letter for their eschar removal treatment, NexoBrid. The FDA was not able to inspect the company's manufacturing facilities due to pandemic travel restrictions.

News for MediWound Stock (MDWD)